Published in J Clin Endocrinol Metab on December 01, 2003
Optimized clinical performance of growth hormone with an expanded genetic code. Proc Natl Acad Sci U S A (2011) 1.20
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) (2008) 0.92
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) (2009) 0.88
Adult growth hormone deficiency: current concepts. Neurol Med Chir (Tokyo) (2014) 0.78
Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults. Clin Exp Immunol (2009) 0.75
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 8.77
The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab (2005) 2.80
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) (2008) 1.78
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2006) 1.73
Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol (2012) 1.62
The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab (2003) 1.61
Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab (2003) 1.60
Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study. Cancer (2010) 1.59
Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem (2011) 1.57
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) (2007) 1.50
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab (2008) 1.42
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. Eur J Endocrinol (2007) 1.42
Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) (2008) 1.32
CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol (2004) 1.29
The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev (2006) 1.24
Endocrine late effects after bone marrow transplant. Br J Haematol (2002) 1.17
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol (2011) 1.13
HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab (2006) 1.12
Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery (2010) 1.11
The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab (2006) 1.11
Do doctors discuss fertility issues before they treat young patients with cancer? Hum Reprod (2008) 1.10
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer (2009) 1.09
Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab (2005) 1.09
Hypopituitarism following Radiotherapy Revisited. Endocr Dev (2009) 1.06
Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab (2005) 1.05
Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol (2006) 1.03
Hypopituitarism following radiotherapy. Pituitary (2009) 1.02
Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin Endocrinol (Oxf) (2007) 1.02
Editorial: acromegaly--consensus, what consensus? J Clin Endocrinol Metab (2002) 1.01
Regulation of cortisol bioavailability--effects on hormone measurement and action. Nat Rev Endocrinol (2012) 0.98
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol (2008) 0.98
Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) (2014) 0.96
Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Genet Metab (2002) 0.95
The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol (2009) 0.95
Impact of growth hormone status on body composition and the skeleton. Horm Res (2004) 0.95
Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res (2002) 0.95
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab (2005) 0.94
Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf (2008) 0.94
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. J Clin Endocrinol Metab (2005) 0.94
Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab (2009) 0.93
Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance. Am J Physiol Endocrinol Metab (2002) 0.93
The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol (2005) 0.92
Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol (2006) 0.92
Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. Eur J Endocrinol (2002) 0.92
Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol (2010) 0.92
Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab (2004) 0.91
Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol (2009) 0.91
CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics (2004) 0.91
Iodothyronine deiodinase enzyme activities in bone. Bone (2008) 0.91
Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab (2010) 0.91
Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) (2005) 0.91
Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm IGF Res (2005) 0.90
The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clin Endocrinol (Oxf) (2009) 0.89
IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer (2005) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Cranial irradiation and growth hormone neurosecretory dysfunction: a critical appraisal. J Clin Endocrinol Metab (2007) 0.88
Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm IGF Res (2003) 0.88
Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep (2002) 0.88
Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol (2005) 0.87
Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab (2004) 0.87
Current status and future opportunities for controlling acromegaly. Pituitary (2002) 0.87
A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clin Endocrinol (Oxf) (2012) 0.87
Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocr Pract (2007) 0.87
Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol (2013) 0.87
Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf) (2013) 0.87
Adult GH deficiency throughout lifetime. Eur J Endocrinol (2009) 0.86
Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary (2005) 0.86
Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab (2004) 0.86
Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab (2011) 0.86
A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab (2005) 0.86
A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. Eur J Endocrinol (2012) 0.85
Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) (2007) 0.84
Hypothyroidism following childhood cancer therapy-an under diagnosed complication. Int J Cancer (2011) 0.84
Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. J Clin Endocrinol Metab (2005) 0.84
Lipid profiles in untreated severe congenital isolated growth hormone deficiency through the lifespan. Clin Endocrinol (Oxf) (2002) 0.84
Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab (2002) 0.84
Growth hormone replacement throughout life: insights into age-related responses to treatment. Growth Horm IGF Res (2007) 0.84
Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol (Oxf) (2003) 0.84
Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem (2010) 0.84
Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) (2013) 0.83
Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab (2002) 0.83
Diabetes, insulin therapy, and colorectal cancer. BMJ (2005) 0.83
Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric Cushing's disease. Clin Endocrinol (Oxf) (2013) 0.83
Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. Circulation (2004) 0.82
Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Horm IGF Res (2006) 0.82
Ultrastructural preservation of ovarian cortical tissue cryopreserved in dimethylsulfoxide for subsequent transplantation into young female cancer patients. Ultrastruct Pathol (2005) 0.82
Differential effects of GH replacement on the components of the leptin system in GH-deficient individuals. J Clin Endocrinol Metab (2002) 0.82
GH responsiveness varies during the menstrual cycle. Eur J Endocrinol (2005) 0.82
Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metab (2014) 0.81
Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab (2001) 0.81
GH replacement reduces increased lipid peroxidation in GH-deficient adults. Clin Endocrinol (Oxf) (2007) 0.81
Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab (2003) 0.81
The insulin-like growth factor-I generation test: peripheral responsiveness to growth hormone is not decreased with ageing. Clin Endocrinol (Oxf) (2003) 0.81
The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J Clin Endocrinol Metab (2003) 0.81
Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab (2005) 0.81
Partial growth hormone deficiency is associated with an adverse cardiovascular risk profile and increased carotid intima-medial thickness. Clin Endocrinol (Oxf) (2010) 0.80